Market Open
Home Calendar Movers Compare
S&P 500 748.17 +0.79% Nasdaq 719.79 +0.71% Dow 30 500.86 +0.75% Apple 298.21 -0.22% Nvidia 177.39 +0.93% Tesla 443.30 -0.44%
Market Open | 468 companies reporting this week
Home / Calendar / LGND

LGND

Ligand Pharmaceuticals Inc - Class B
$218.98
90-day price trend
-1.01% ($2.23)
Volume 151,157
52W High $247.38
52W Low $98.89
Market Cap $2.82B
← Back to Calendar Compare with Others →

Next Earnings Report

Last Reported
May 13, 2026 Missed
Actual: $1.63 vs. Consensus: $1.65

Price Chart

EPS History: Consensus vs Actual

Last 10 quarters

Price Movement Around Earnings

Q1 2026 May 13, 2026
1-Day: -1.01%
Q1 2026 May 7, 2026
1-Day: +5.27%
5-Day: +5.55%
Q4 2025 Mar 4, 2026
1-Day: -1.28%
5-Day: -0.38%
Q4 2025 Feb 26, 2026
1-Day: +1.09%
5-Day: +4.11%

Revenue & Financial Performance

Quarter Revenue YoY Growth Gross Margin Op Margin Net Income
Q4'25 $59.7M +39.4% 143.6% 33.6% $44.8M
Q3'25 $115.5M +122.9% 78.5% 47.6% $117.3M
Q2'25 $47.6M +14.7% 93.9% 17.7% $4.8M
Q1'25 $45.3M +46.3% 89.3% -79.9% -$42.5M
Q4'24 $42.8M +52.4% 93.4% -22.5% -$31.1M
Q3'24 $51.8M +57.6% 75.9% 6.1% -$7.2M
Q2'24 $41.5M +57.5% 136.9% -46.0% -$51.9M
Q1'24 $31.0M -29.6% 64.3% 9.7% $86.1M

Historical Earnings

Last 12 quarters
Quarter Date Consensus Whisper Actual EPS Surprise % Result
Q1 2026 May 13, 2026 $1.65 $1.83 $1.63 -1.21% Missed
Q1 2026 May 7, 2026 $1.80 $1.99 -- -- --
Q4 2025 Mar 4, 2026 $1.49 $1.59 $2.02 +35.57% Beat
Q4 2025 Feb 26, 2026 $1.50 $1.61 -- -- --
Q3 2025 Nov 6, 2025 $1.93 $2.04 $3.09 +60.10% Beat
Q2 2025 Aug 8, 2025 $1.43 $1.64 $0.24 -83.22% Missed
Q1 2025 May 5, 2025 $0.78 $0.90 $1.33 +70.51% Beat
Q4 2024 Feb 25, 2025 $1.19 $1.37 $1.27 +6.71% Missed
Q3 2024 Nov 7, 2024 $1.35 $1.55 $1.84 +36.30% Beat
Q2 2024 Aug 6, 2024 $1.06 $1.22 $1.40 +32.08% Beat
Q1 2024 May 7, 2024 $0.78 $0.90 $1.20 +53.85% Beat
Q4 2023 Feb 27, 2024 $0.66 $0.76 $1.38 -- Beat

Company Information

Symbol
LGND
Company
Ligand Pharmaceuticals Inc - Class B
Market Cap
$2.82B
include __DIR__ . '/includes/footer.php'; ?>